What’s the current market cap for Day One Biopharmaceuticals stock?

Day One Biopharmaceuticals (DAWN) has a market cap of $2.2bn as of June 15, 2026.

What is the P/E ratio for Day One Biopharmaceuticals stock?

The price to earnings (P/E) ratio for Day One Biopharmaceuticals (DAWN) stock is 0 as of June 15, 2026.

Does Day One Biopharmaceuticals stock pay dividends?

No, Day One Biopharmaceuticals (DAWN) stock does not pay dividends to its shareholders as of June 15, 2026.

When is the next Day One Biopharmaceuticals dividend payment date?

Day One Biopharmaceuticals (DAWN) stock does not pay dividends to its shareholders.

What is the beta indicator for Day One Biopharmaceuticals?

Day One Biopharmaceuticals (DAWN) has a beta rating of -1.27. This means that it has an inverse relation to market volatility.

Buy Day One Biopharmaceuticals stock | $DAWN Share Price

13:30

09:10

04:45

00:25

20:00

About Day One Biopharmaceuticals

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.

Ticker

$DAWN

Sector

Health

Primary listing

NASDAQ

Employees

178

Headquarters

Brisbane, United States

Website

dayonebio.com

DAWN Metrics

BasicAdvanced

$2.2bn

-$1.04

-1.27

What the Analysts think about DAWN

Analyst ratings (Buy, Hold, Sell) for Day One Biopharmaceuticals stock.

Bulls say / Bears say

Day One’s pediatric glioma drug OJEMDA generated $158 million in the last twelve months with an 89% gross profit margin, demonstrating robust commercial traction and cash flow potential (Reuters).

Servier’s all-cash tender offer at $21.50 per share values Day One at $2.5 billion, validating the strategic importance and investor confidence in the company’s oncology platform (Reuters).

The January 2026 acquisition of Mersana Therapeutics added the clinical-stage ADC Emi-Le to Day One’s pipeline, broadening its targeted therapy portfolio beyond pediatric glioma and enhancing future growth prospects (Reuters).

Over 90% of Day One’s revenue comes from its single approved product, OJEMDA, exposing the company to significant concentration risk until other pipeline assets are commercialized (Reuters).

The $129 million upfront cash payment plus up to $30.25 per share in contingent milestone rights for the Mersana acquisition introduces potential dilution and integration challenges that could pressure margins (Reuters).

Key pipeline catalysts carry binary outcomes, with FIREFLY-2 enrollment only completing in H1 2026 and initial DAY301 clinical data not due until H2 2026, heightening the risk of trial delays or setbacks (Reuters).

Data summarised monthly by Lightyear AI. Last updated on 3 Jun 2026.

DAWN Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

DAWN Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $DAWN

Capital at risk

Market open

Upcoming events

No upcoming events

Bulls say / Bears say

Day One’s pediatric glioma drug OJEMDA generated $158 million in the last twelve months with an 89% gross profit margin, demonstrating robust commercial traction and cash flow potential (Reuters).

Servier’s all-cash tender offer at $21.50 per share values Day One at $2.5 billion, validating the strategic importance and investor confidence in the company’s oncology platform (Reuters).

Over 90% of Day One’s revenue comes from its single approved product, OJEMDA, exposing the company to significant concentration risk until other pipeline assets are commercialized (Reuters).

Data summarised monthly by Lightyear AI. Last updated on 3 Jun 2026.